| 000 | 02757nam a22002897a 4500 | ||
|---|---|---|---|
| 003 | OSt | ||
| 005 | 20260727095226.0 | ||
| 008 | 260727s2025 |||||||| |||| 00| 0 eng d | ||
| 050 | _aT MTech A58c 2025 | ||
| 100 | _aCasaul, Karen L. | ||
| 245 |
_aAntimycotic activity of chitosan derived from Litopenaeus vannamei (whiteleg shrimp) shells against candida auris / _cKaren L. Casaul, [and seven others]. |
||
| 264 |
_aEmilio Aguinaldo College Cavite : _bSchool of Medical Technology, _c2025. |
||
| 300 |
_aviii, 103 pages : _bcolored illustration ; _c28 cm. |
||
| 336 |
_2rdacontent _atext |
||
| 337 |
_2rdamedia _aunmediated |
||
| 338 |
_2rdacarrier _avolume |
||
| 504 | _aIncludes bibliographic references. | ||
| 520 | _aABSTRACT - - Candida auris is a rising threat in healthcare due to its ability to resist many antifungal drugs and cause serious infections. Because of this, there is an urgent need for alternative treatments. This study aimed to evaluate the antimycotic activity of chitosan extracted from Litopenaeus vannamei (Whiteleg Shrimp) shells against clinical isolates of Candida auris. Chitosan was obtained through demineralization, deproteinization, and deacetylation processes, then confirmed through X-ray diffraction and Fourier-transform infrared spectroscopy. Moreover, to assess antifungal activity, two isolates of C. auris were exposed to different concentrations of chitosan using the broth microdilution method and Kirby-Bauer disk diffusion test. As a result, a distinct dose dependent effect was seen in the data, with greater chitosan concentrations (up to 1000 μg/mL) inhibiting fungal growth more successfully than lower concentrations, particularly in wound isolates. Furthermore, the clinical isolate from the ear canal was resistant to Amphotericin B, although it was still susceptible to the majority of chitosan concentrations, Caspofungin, and Fluconazole. Every treatment was effective on the wound alone. Additionally, these results imply that chitosan, a naturally occurring substance made from seafood waste, may be a viable and sustainable substitute for manufactured antifungal medications, particularly when treating resistant strains such as C. Auris. Opportunities for the advancement of shell-based antifungal drugs in pharmaceutical and medical applications are also presented by this work. | ||
| 700 |
_4Author. _aMontehermoso, Colleen C. |
||
| 700 |
_4Author. _aPaguntalan, Angeline D. |
||
| 700 |
_4Author. _aPakinggan, Louise Jasrhel S. |
||
| 700 |
_4Author. _aRamos, Airish Keight P. |
||
| 700 |
_4Author. _aRogacion, Yzzhi Dominique A. |
||
| 700 |
_4Author. _aValmoria, Athena Joy P. |
||
| 700 |
_4Author. _aZamora, Jade Lynn P. |
||
| 942 |
_2lcc _cTH _kEAC Cavite-Thesis |
||
| 999 |
_c100208 _d100208 |
||